Skip to content

Study of Mouse Nerve Growth Factor Intravitreous Injection for Retinitis pigmentosa

Safety and Efficacy Study of Mouse Nerve Growth Factor Intravitreous Injection for Retinitis pigmentosa

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TNRC-09000411
Enrollment
Unknown
Registered
2009-05-29
Start date
2008-05-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinitis Pigmentosa (RP)

Interventions

Typical RP group:Intravitreous Injection for typical Retinitis pigmentosa Intravitreous Injection for typical ietti crystalline corneoretinal dystrophy
Bietti crystalline corneoretinal dystrophy group:Intravitreous Injection for typical Retinitis pigment

Sponsors

Southwest Hospital, Third Military Medical Universi
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. Clinical condition, bilateral expression of advanced typical retinitis pigmentosa and Bietti crystalline corneoretinal dystrophy (a form of autosomal recessive retinitis pigmentosa); 2. Age range 18 to 50 years; 3. Visual acuity is better than 20/200 and worse than 20/30 by ETDRS vision testing in the operated eye, or the radius of view is better than10 degree less than 30 degree by visual field testing. Vision in the non-operated eye must be better than the operated eye; 4. Patient has signed informed consent for NGF intravitreous injection and is willing to return for follow-up visits; 5. Macular has no detectable gross changes either clinically or on fluorescein angiography.

Exclusion criteria

Exclusion criteria: 1. Patient has medical problems that have a high risk of general anesthesia, such as metabolic, cadiovascular, hematopoietic or psychological system disorders; 2. Women in menstruation, pregnancy, perinatal prtiod and baby nursing periods; 3. Any significant ocular disease that has compromised or could compromise vision in the study eye and confound analysis of the primary outcome; 4. Patient who has a history of corneal leukoma, cataract, uveitis, Coat's disease, diabetic retinopathy, glaucoma, or vitreous opacities that prevents visualization of the posterior pole; 5. Participating in another ophthalmic clinical trial or use of any other investigational new drugs within 3 months before the start of study treatment; 6. Intraocular surgery within the last 3 months.

Design outcomes

Primary

MeasureTime frame
Flash electroretinography;Multifocal electroretinography;Pupillary light reflex;Optical coherent tomography;Fluorescein angiography;Static perimetry;Snellen Visual acuit;

Countries

China

Contacts

Public ContactYin Zhengqin
qinzyin@yahoo.com.cn+86 023 68754401

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026